Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban

The HAS-BLED, ATRIA, and ORBIT Bleeding Scores in Atrial Fibrillation Patients Using Non-Vitamin K Antagonist Oral Anticoagulants

(2018) Gregory Y.H. Lip et al.   AMERICAN JOURNAL OF MEDICINE

Long-term adverse effects of paracetamol - a review

(2018) J. C. McCrae et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly

(2018) Supakanya Wongrakpanich et al.   Aging and Disease

The future of atrial fibrillation management: integrated care and stratified therapy

(2017) Paulus Kirchhof   LANCET

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

(2016) Paulus Kirchhof et al.   EUROPEAN HEART JOURNAL

Level of Blood Pressure Control and Cardiovascular Events

(2016) Min Jung Ko et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study

(2016) Ziad Hijazi et al.   LANCET

Paracetamol, Ibuprofen, and Recurrent Major Cardiovascular and Major Bleeding Events in 19 120 Patients With Recent Ischemic Stroke

(2016) Jaime Gonzalez-Valcarcel et al.   STROKE

Characterizing Major Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Pharmacovigilance Study of 27 467 Patients Taking Rivaroxaban

(2015) Sally Tamayo et al.   CLINICAL CARDIOLOGY

XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation

(2015) A. John Camm et al.   EUROPEAN HEART JOURNAL

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary

(2014) Craig T. January et al.   CIRCULATION

Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe

(2014) Raffaele De Caterina et al.   HEART

Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people

(2014) Eleni Rapsomaniki et al.   LANCET

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

(2013) Christian T Ruff et al.   LANCET

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

(2013) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation

(2012) J. M. L. Hendriks et al.   EUROPEAN HEART JOURNAL

A New Risk Scheme to Predict Warfarin-Associated Hemorrhage

(2011) Margaret C. Fang et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation

(2010) Ron Pisters et al.   CHEST

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE